港股異動 | 錦欣生殖(1951.HK)漲5.94% 收購深圳中山醫院5.46%股權 控股權增至約99.9%
格隆匯4月14日丨錦欣生殖(1951.HK)漲5.94%,報6.06港元,總市值151億港元。該公司昨日發佈公吿,於2022年4月13日,買方成都錦潤福德醫療管理有限公司(公司因現有合約安排而持有的間接附屬公司)與曾勇訂立股權轉讓協議,據此,買方同意根據其條款及條件購買而曾同意出售深圳中山醫院的5.46%股權,代價為1.575億港元。於收購事項完成後,公司將間接持有深圳中山醫院的70.00%股權,並透過合約安排控制深圳中山醫院的29.90%股權。因此,深圳中山醫院將繼續為公司的非全資附屬公司,深圳中山醫院的財務業績將繼續於集團的財務報表綜合入賬,並基於與核數師的討論,公司已確認根據現行會計原則有權如此行事。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.